Modified LCAT Enzyme for Atherosclerosis Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for atherosclerosis and related conditions, such as coronary heart disease, often focus on reducing LDL cholesterol levels but are unclear in their benefits for patients with low HDL cholesterol, and existing methods lack effective solutions for increasing HDL levels and preventing cholesterol accumulation in arterial walls.
Innovation Solution
Modification of lecithin-cholesterol acyltransferase (LCAT) enzyme to enhance its activity and stability, specifically by replacing the amino acid residue 31 with a cysteine residue modified by 3-pyrazinyl-2-carbonitrile, which is administered to increase HDL cholesterol levels and prevent cholesterol accumulation in arterial walls.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If statins are used to reduce LDL cholesterol levels, then the risk for atherosclerosis is reduced, but the benefit for patients with low HDL cholesterol levels remains unclear
Solution Approach 1:
The patent modifies the LCAT enzyme through site-directed mutagenesis, specifically replacing amino acid residue 31 with cysteine and subsequently modifying it with 3-pyrazinyl-2-carbonitrile. This parameter change in the enzyme structure results in enhanced enzymatic activity and stability, thereby improving HDL cholesterol levels and addressing the limitation of statin therapy for patients with low HDL cholesterol.
2Quantity of substance
If LCAT enzyme activity is enhanced through modification, then HDL cholesterol levels increase and cholesterol accumulation in arterial walls is prevented, but the enzyme stability and activity must be maintained under physiological conditions
Solution Approach 1:
The patent modifies the LCAT enzyme through site-directed mutagenesis, specifically replacing amino acid residue 31 with cysteine and subsequently modifying it with 3-pyrazinyl-2-carbonitrile. This parameter change in the enzyme structure results in enhanced enzymatic activity and stability, thereby improving HDL cholesterol levels and addressing the limitation of statin therapy for patients with low HDL cholesterol.
Solution Approach 2:
The patent employs a small molecule modifier (3-pyrazinyl-2-carbonitrile) that can be easily attached to the modified cysteine residue. This small molecule serves as a stable, long-lasting modification that permanently enhances the enzyme's activity and stability without requiring continuous replenishment or complex maintenance.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified LCAT enzyme effectively increases HDL cholesterol levels, reduces cholesterol accumulation in arterial walls, and treats conditions associated with atherosclerosis, inflammation, and thrombosis, providing a therapeutic approach for patients with low HDL cholesterol levels.
Implementation Method 1
Lecithin-cholesterol acyltransferase (LCAT) is an enzyme which catalyzes the esterification of free cholesterol by the transfer of an acyl group from phosphatidylcholine onto 3-hydroxyl group of the cholesterol, forming cholesteryl ester and lysophosphatidylcholine
Data Source
AI summary
The invention provides compounds, pharmaceutical compositions and methods for treating atherosclerosis, inflammation, thrombosis and other conditions and for decreasing or prevention of accumulation of cholesterol in a subject by modifying LCAT polypeptide.